On July 1, Orchid Pharma partnered with Cipla to launch the antibiotic Cefepime-Enmetazobactam in India, according to an exchange filing.
Today we announced that we’ve exercised our option to convert our ongoing co-development and co-commercialization agreement with Orion Corporation into an exclusive global license. Learn more: https://t.co/9R6YV5nLS3 https://t.co/cjdP3RE5NK
$BMY axes another big alliance -- sayonara $650M https://t.co/R9UnGQLgO9
Dreaded “portfolio prioritisation” at BMS sees end to ADC deal with Eisai. Bristol Myers Squibb paid $650 million upfront back in 2021. 🫣 $BMY https://t.co/f6e1iFGY3Q
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) $AMRX https://t.co/JxqdilmxEH
Herbalife Nutrition announces plans to release second quarter 2024 financial results on July 31 following NYSE closing. Webcast hosted by management scheduled for 5:30PM ET. Stay updated with $HLF #Q2Earnings.
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30 $MRK https://t.co/AC97i6Eyyh
#OrchidPharma partners with #Cipla to launch antibiotic Cefepime-Enmetazobactam in #India: Exchange filing